Clinical Report: FDA Revises Monitoring for SCLC Therapy

Overview

The FDA has updated the prescribing information for tarlatamab-dlle, reducing the recommended monitoring time after the first two doses for patients with extensive-stage small cell lung cancer from 22-24 hours to 6-8 hours.

Background

Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with limited treatment options. Tarlatamab is a targeted immunotherapy that has shown promise in treating SCLC, necessitating careful monitoring for adverse effects.

Data Highlights

No numerical data provided in the article.

Key Findings

• The FDA reduced the monitoring time for tarlatamab-dlle from 22-24 hours to 6-8 hours after the first two doses.
• Patients must still be monitored for 6-8 hours after the third dose and throughout cycle 2.
• Monitoring time decreases to 3-4 hours during cycles 3 and 4, and to 2 hours during cycle 5 and subsequent doses.
• Cytokine release syndrome occurred in 57% of patients in a pooled safety population, with 2% experiencing grade 3 events.
• Neurologic toxicity was reported in 65% of patients, with 7% experiencing grade 3 or higher events.
• Patients must remain within 1 hour of a healthcare setting for 48 hours after specific doses.

Clinical Implications

Clinicians should remain vigilant for potential adverse effects, particularly cytokine release syndrome and neurologic toxicity, during the specified monitoring periods.

Conclusion

The FDA's update on monitoring for tarlatamab-dlle provides new guidelines for patient management.

Related Resources & Content

1. Amgen, FDA Approves Reduced Monitoring Time for First Two Doses of IMDELLTRA®, 2026 -- FDA Approves Reduced Monitoring Time for First Two Doses of IMDELLTRA®
2. ASCO Post, Extended-Interval Dosing of Tarlatamab Found Safe, Effective in SCLC, 2026 -- Extended-Interval Dosing of Tarlatamab Found Safe, Effective in SCLC
3. ASCO Post, ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC, 2023 -- ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC
4. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2026, 2026 -- NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2026
5. The ASCO Post — Novel Therapies for Small Cell Lung Cancer and Neuroendocrine Tumors
6. the asco post — FDA Approves Combination Regimen for Extensive-Stage SCLC
7. FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA® | Amgen Inc.
8. NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026 - PubMed
9. Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis - PubMed